The work is being coordinated by AGTC under an agreement with researchers at Oregon Health & Science University Casey Eye Institute, David Wilson and The University of Florida, William Hauswirth.
AGTC president and CEO Sue Washer said this funding will enable them to finish final testing of the treatment in animal models of XLRS as well as complete the pre-clinical safety studies required by the FDA in order to start a Phase 1 human clinical trial.